Acta Biomater, 2016 · DOI: 10.1016/j.actbio.2016.02.013 · Published: April 15, 2016
Spinal cord injuries often result in permanent motor and sensory deficits due to the limited regenerative capacity of the adult central nervous system. Nucleic acid-based therapies are a promising strategy for delivering bioactive molecules that can promote axonal regeneration. The study introduces a novel nonviral vector, poly (lactide-co-glycolide)-graft-polyethylenimine (PgP) micelle, capable of efficiently delivering plasmid DNA (pDNA) and siRNA in the presence of serum. The developed PgP copolymer enhances transfection and reduces cytotoxicity in neural cells both in vitro and in vivo, suggesting its potential as a nonviral vector for therapeutic nucleic acid delivery aimed at neural regeneration.
PgP may be a useful therapeutic nucleic acids delivery carrier for the treatment of spinal cord injury, as well as other forms of CNS trauma and neurodegenerative diseases.
Future studies will extend the capabilities of PgP through conjugation of neuron-specific targeting ligands for siRNA delivery and hydrophobic drug loading within the micelle core.
PgP's ability to deliver both genes and drugs makes it a promising candidate for combinatorial therapy strategies in treating SCI.